Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level <30ng/ml) Cholecalciferol. 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 6 months

Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level<30ng/ml) Placebo than cholecalciferol. 5 doses of placebo in 3 months than 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 3 months.

Drug Resistant Epilepsy

Cholecalciferol

Placebo Oral

Vitamine D in Drug Resistant Epilepsy

Effect of the Treatment of Vitamin D Deficiency in Drug-resistant Epilepsy

Total score at baseline and after Vitamin D treatment (range 0-200; higher values=worse outcome)

Total score at baseline and after Vitamin D treatment (range 0-42; higher values=worse outcome)

Global score at baseline and after Vitamin D treatment (the higher score, the better outcome)

Vitamin D levels and percentage reduction in the seizure frequency compared to the reference period

Vitamin D level and type of AED (enzyme inducer versus non enzyme inducer drugs)

Vitamin D level and dose of AED (low dose versus high dose of enzyme inducer drugs)

Responder rate after Vitamin D treatment. Percentage of patients having a reduction of at least 50% of the seizure frequency

Percentage of patients without any seizure (seizure freedom)

Responder rate in focal and generalized epilepsy

Percentage of reduction of secondary generalized seizures and epileptic falls in respect to the reference period

Centre Hospitalier St Anne

APHP

FFRE

LFCE

Myeloid Leukemia, Chronic

Rigshospitalet

Helsinki University Central Hospital

University of Freiburg

University of Muenster

St Ivan & St Laszlo Hospital

Chaim Sheba Medical Centre

Medical University of Silesia

St Petersburg State Medical Pavlov University

King Faisal Specialist Hospital & Research Centre

Hammersmith

Effect of 2nd Gen TKI in CML

Effect of Prior Therapy With Nilotinib or Dasatinib on the Outcome After Allogeneic Stem Cell Transplantation for Patients With Chronic Myeloid Leukaemia

European Group for Blood and Marrow Transplantation

Novartis

Patients with documented fibromuscular dysplasia (see inclusion criteria).
Non-usual care added acts:
blood sampling
urine sampling
renal echography

paris/cefalea

Vitamine D in Drug Resistant Epilepsy

Effect of 2nd Gen TKI in CML

Cross-sectional Study of Patients With Renal or Craniocervical Fibromuscular Dysplasia

La base de datos de hierbas medicinales más completa respaldada por la ciencia